News Website

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today

Published: Dec. 18, 2024, 8:16 p.m.

Read Full Article

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome - ResearchGate

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome ResearchGate

Published: Dec. 3, 2024, 6:33 a.m.

Read Full Article

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers - OncLive

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers OncLive

Published: Nov. 14, 2024, 8:14 p.m.

Read Full Article

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - StreetInsider.com

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors StreetInsider.com

Published: Oct. 29, 2024, 10:11 a.m.

Read Full Article

Efficacy, Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer - Medpage Today

Efficacy, Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer Medpage Today

Published: Oct. 23, 2024, 2:47 p.m.

Read Full Article

MSK Endometrial Cancer e-Tumor Board - Medscape

MSK Endometrial Cancer e-Tumor Board Medscape

Published: July 12, 2024, 7 a.m.

Read Full Article

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod - FiercePharma

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod FiercePharma

Published: April 8, 2024, 7 a.m.

Read Full Article

CLDN6-23-ADC shows promise for ovarian, endometrial tumors - BioWorld Online

CLDN6-23-ADC shows promise for ovarian, endometrial tumors BioWorld Online

Published: Feb. 29, 2024, 8 a.m.

Read Full Article

The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway | Cell Death & Disease - Nature.com

The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway | Cell Death & Disease Nature.com

Published: Jan. 18, 2024, 8 a.m.

Read Full Article

Latest Articles

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome - ResearchGate

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers - OncLive

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - StreetInsider.com

Efficacy, Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer - Medpage Today

MSK Endometrial Cancer e-Tumor Board - Medscape

AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod - FiercePharma

CLDN6-23-ADC shows promise for ovarian, endometrial tumors - BioWorld Online

The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway | Cell Death & Disease - Nature.com

Subscribe to Our Newsletter